Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Morphologic evidence of B-precursor ALL with \> 25% blasts in bone marrow (M3) at study enrolment~* Age less than 18 years at enrollment~* Relapsed/refractory disease:~  * Second or later bone marrow relapse,~ * Any marrow relapse after allogeneic hematopoietic stem cell transplantation (HSCT), or~ * Refractory to other treatments: Patients in first relapse must have failed to achieve a CR following full standard reinduction chemotherapy regimen of at least 4 weeks duration. Patients who have not achieved a first remission must have failed a full standard induction regimen~* Karnofsky performance status more than or equal to 50% for patients more than or equal to 16 years and Lansky Performance Status (LPS) of more than or equal to 50% for patients less than 16 years~* Organ function requirements: All patients must have adequate renal and liver functions~Exclusion Criteria:~* Active acute or extensive chronic graft-versus-host disease (GvHD)~* Immunosuppressive agents to prevent or treat GvHD within 2 weeks prior to blinatumomab treatment~* Evidence for current central nervous system (CNS) involvement by ALL (CNS 2, CNS 3) or testicular involvement by ALL~* History of relevant CNS pathology or current relevant CNS pathology~* History of autoimmune disease with potential CNS involvement or current autoimmune disease~* Any HSCT within 3 months prior to blinatumomab treatment~* Cancer chemotherapy within 2 weeks prior to blinatumomab treatment (except for intrathecal chemotherapy and/or low dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, glucocorticoids)~* Chemotherapy related toxicities that haven't resolved to less than or equal to Grade 2~* Radiotherapy within 2 weeks prior to blinatumomab treatment~* Immunotherapy (e.g. rituximab, alemtuzumab) within 6 weeks prior to blinatumomab treatment~* Any investigational product within 4 weeks prior to study entry~* Previous treatment with blinatumomab~* Active severe infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol~* Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HbsAg positive) or hepatitis C virus (anti-HCV positive)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Blinatumomab (Type: EXPERIMENTAL): Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).